Julia Carnevale, Eric Shifrut, Nupura Kale, William A Nyberg, Franziska Blaeschke, Yan Yi Chen, Zhongmei Li, Sagar P Bapat, Morgan E Diolaiti, Patrick O'Leary, Shane Vedova, Julia Belk, Bence Daniel, Theodore L Roth, Stefanie Bachl, Alejandro Allo Anido, Brooke Prinzing, Jorge Ibañez-Vega, Shannon Lange, Dalia Haydar, Marie Luetke-Eversloh, Maelys Born-Bony, Bindu Hegde, Scott Kogan, Tobias Feuchtinger, Hideho Okada, Ansuman T Satpathy, Kevin Shannon, Stephen Gottschalk, Justin Eyquem, Giedre Krenciute, Alan Ashworth, Alexander Marson
The efficacy of adoptive T cell therapies for cancer treatment can be limited by suppressive signals from both extrinsic factors and intrinsic inhibitory checkpoints1,2 . Targeted gene editing has the potential to overcome these limitations and enhance T cell therapeutic function3-10 . Here we performed multiple genome-wide CRISPR knock-out screens under different immunosuppressive conditions to identify genes that can be targeted to prevent T cell dysfunction. These screens converged on RASA2, a RAS GTPase-activating protein (RasGAP) that we identify as a signalling checkpoint in human T cells, which is downregulated upon acute T cell receptor stimulation and can increase gradually with chronic antigen exposure...
September 2022: Nature